739986
Last Update Posted: 2023-11-09
Recruiting has ended
All Genders accepted | 18 Years + |
152 Estimated Participants | No Expanded Access |
Interventional Study | Does not accept healthy volunteers |
Semapimod for Treatment of Moderate to Severe Crohn's Disease 1 or 3 Days' Treatment Versus Placebo
Assessment of the number of days' treatment with semapimod necessary for efficacy, as measured by response rate to CNI-1493 as compared to placebo, in patients with moderate to severe Crohn's disease (CD).
Eligibility
Relevant conditions:
Crohn's Disease
If you aren't sure if you meet the criteria above speak to your healthcare professional. Criteria may be updated but not reflected here, do not hesitate to contact the study if you think are close to fitting criteria.
locations
Data sourced from ClinicalTrials.gov